Eisai and Abbott Signed a Joint Development Agreement for new indication, psoriasis, of anti-rheumatic agent D2E7 (adalimumab)
13-Apr-2005 -
Eisai Co., Ltd. and Abbott Japan Co., Ltd. announced that Eisai and Abbott GmbH & Co., KG signed a supplemental agreement for the joint development of the new indication, psoriasis, of the anti-rheumatic agent D2E7 (Generic Name: adalimumab, fully human anti-TNF-alpha monoclonal antibody) in ...
Abbott
Crohn's disease
diseases
+3